argenx Launches $77 Per Share Cash Tender Offer for Forte Biosciences

Key Facts

In a move reflecting the ongoing consolidation within the biotechnology sector, argenx has officially launched a cash tender offer to acquire Forte Biosciences (FBRX). The offer entails purchasing all outstanding shares for $77.00 per share in cash through its subsidiary, Avena Merger Sub Inc. This commencement follows the merger agreement initially dated July 26, 2026, and serves as the formal execution to integrate Forte Biosciences into argenx's specialized immunology portfolio.

According to reports, this tender offer is the strategic culmination of a planned merger aimed at scaling argenx's innovation capabilities. This corporate action coincides with broader economic shifts, as market data from July 30, 2026, showed U.S. GDP growth slowing to 1.5%. The acquisition is viewed as a definitive move providing a guaranteed cash exit for Forte Biosciences shareholders at a specific premium, amidst a complex macroeconomic environment for mid-cap biotech firms.

Investors should monitor the progression of the tender offer following its official start on August 6, 2026. While current instrument prices are unavailable at this snapshot, market sentiment remains influenced by inflation data, such as the Core PCE Price Index which rose by 0.1% as of July 30, 2026. Future catalysts for the sector may depend on how these broader economic indicators impact the financing and valuation of similar M&A activities.